mAbs in nonlupus autoimmune rheumatic disease

Current Opinion in Hematology

Volumn 16, Issue 4, 2009, Pages 280-284

  Whelan, Bryan R ^a   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antitumour necrosis factor ; Myositis; Rituximab; Sjogren's vasculitis

Indexed keywords

ATLIZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AORTA ARCH SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DRUG EFFICACY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HUMAN; IDIOPATHIC IMMUNE MYOSITIS; INCLUSION BODY MYOSITIS; LIVER CIRRHOSIS; MYOSITIS; OPEN STUDY; PERIPHERAL NEUROPATHY; POLYMYOSITIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN DEFECT; SOLID TUMOR; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; RHEUMATIC DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67749137414     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32832c1f53     Document Type: Review

References (50)

1. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology biologics register. Ann Rheum Dis 2003; 62 (Suppl 2):ii28-ii29.
2. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumour necrosis factor alpha therapy: results from the British Society for Rheumatology biologics register. Ann Rheum Dis 2009; 68:209-215.
3. Kay LJ, Griffiths ID. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. Rheumatology (Oxford) 2006; 45:1376-1379.
4. Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol 2008:163-181.
5. Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 2006; 77:24-28.
6. Dorner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008; 20:263-268.
7. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971-982.
8. Hewer E, Goebel HH. Myopathology of noninfectious inflammatory myopathies: The current status. Pathol Res Pract 2008; 204:609-623.
9. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601-607.
10. Sultan SM, Ng KP, Edwards JC, et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 2008; 26:887-893. Largest open-label study of rituximab in myositis demonstrating better efficacy in Jo-1-positive patients.
11. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33:1021-1026.
12. Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008; 75:334-337.
13. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007; 34:1864-1868.
14. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromusc Disord 2006; 16:334-336.
15. Whelan BR, Isenberg DA. Poor response of anti SRP positive idiopathic immune myositis to B cell depletion. Rheumatology (Oxford) 2009; 48:594-595.
16. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65:1233-1236.
17. Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802-1804.
18. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with antitumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004; 52:61-63.
19. Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNFalpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159-163. Open-label study of anti-TNFa in myositis demonstrating the difficulties in conducting studies on patients with myositis.
20. Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 2007; 46:1389-1396.
21. Somer BG, Tsai DE, Downs L, et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003; 49:394-398.
22. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913-920.
23. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740-2750.
24. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284-285. Follow-up study demonstrating the efficacy and tolerability of repeated treatment with rituximab in Sjogren's syndrome.
25. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541-1544. One of the few randomized, double-blind, placebo-controlled studies in this area, demonstrating that rituximab improves quality of life and fatigue more than objective measures of exocrine function.
26. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006; 8:R129.
27. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001; 44:2371-2375.
28. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270-1276.
29. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 2008; 67:1437-1443.
30. Eriksson P. Nine patients with antineutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540-548.
31. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268.
32. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
33. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970-2982.
34. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:2017-2023.
35. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
36. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54:1608-1618.
37. Tedeschi A, Barate C, Minola E, Morra E. Cryoglobulinemia. Blood Rev 2007; 21:183-200.
38. Braun A, Neumann T, Oelzner P, et al. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int 2008; 28:503-506.
39. Evans JT, Shepard MM, Oates JC, et al. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 2008; 42:862-863.
40. Pasa S, Altintas A, Cil T, et al. A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab. J Thromb Thrombolysis 2009; 27:220-222.
41. Pandrangi S, Singh A, Wheeler DE, Rossi NF. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol 2008; 4:393-397.
42. MassariM, Catania A, Magnani G. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Dig Liver Dis 2007; 39 (Suppl 1): S134-S135.
43. Petrarca A, Rigacci L, Monti M, et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis 2007; 39 (Suppl 1):S129-S133.
44. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004; 43:e34-e38.
45. Visentini M, Granata M, Veneziano ML, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007; 125:30-33.
46. Saadoun D, Rosenzwajg M, Landau D, et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111:5334-5341.
47. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20 agent. Blood 2003; 101:3818-3826.
48. Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008; 67:1343-1346.
49. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
50. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody. Arthritis Rheum 2008; 58:1197-1200.